Loading...
•
Dec 31, 2022
Jaguar Health Q4 2022 Earnings Report
Jaguar Health's prescription revenues increased significantly, driven by Mytesi growth and Canalevia-CA1 commercial availability.
Key Takeaways
Jaguar Health reported a 57% increase in prescription product net revenue for Q4 2022 compared to Q4 2021, reaching $3.3 million. The growth was attributed to the continued success of Mytesi and the introduction of Canalevia-CA1. The company is focused on expanding clinical trials and exploring new indications for crofelemer.
Prescription product net revenue increased by 57% in Q4 2022 compared to Q4 2021.
Mytesi revenue continued to grow for the sixth consecutive quarter.
Patient enrollment in the OnTarget Phase 3 clinical trial is at approximately 80% and expected to complete in Q2 2023.
The company plans to support investigator-initiated proof-of-concept studies of crofelemer for short bowel syndrome and congenital diarrheal disorders.
Jaguar Health
Jaguar Health
Forward Guidance
Jaguar Health is focused on completing enrollment in the OnTarget trial, supporting investigator-initiated studies, and submitting an IND application for crofelemer.
Positive Outlook
- Patient enrollment in OnTarget trial expected to complete in Q2 2023.
- Planning to support investigator-initiated proof-of-concept studies of crofelemer in 2023.
- Potential early patient access to crofelemer in Europe in 2024.
- Plans to submit an IND application in Q2 2023 to FDA for crofelemer for microvillus inclusion disease.
- Transition to limited distribution network of specialty pharmacies resulted in a meaningful reduction in Mytesi distribution costs as well as a higher average net price